Plasma suPAR Levels and Early Mortality Risk in HIV Patients
Author Information
Author(s): Stephen D Lawn, Landon Myer, Bangani Nonzwakazi, Monica Vogt, Robin Wood
Primary Institution: Desmond Tutu HIV Centre, University of Cape Town, South Africa
Hypothesis
The study evaluates the practical utility of plasma suPAR in assessing short-term all-cause mortality risk in patients with advanced immunodeficiency enrolling in an antiretroviral treatment programme.
Conclusion
Plasma suPAR concentration was the strongest independent predictor of short-term mortality risk among patients with advanced immunodeficiency, but the lack of a discriminatory threshold limited its clinical utility.
Supporting Evidence
- Higher suPAR concentrations were significantly associated with mortality.
- Patients who died had higher plasma suPAR concentrations compared to those who survived.
- The study included 293 patients with advanced immunodeficiency.
- The median follow-up period was 5 months.
Takeaway
This study looked at a blood test called suPAR to see if it could help doctors figure out which HIV patients might be at risk of dying soon after starting treatment. It found that higher suPAR levels meant a higher risk, but there wasn't a clear cutoff to use it as a reliable test.
Methodology
An enzyme-linked immunosorbent assay (ELISA) was used to measure plasma suPAR concentrations at the time of enrolment, and associations with patient outcomes were analyzed over 4 months.
Potential Biases
Some patients lost to follow-up may have died, which could affect the mortality estimates.
Limitations
The study's findings may not be generalizable to patients with less advanced immunodeficiency, and the lack of a useful cut-point for suPAR concentrations limits its clinical application.
Participant Demographics
Patients had a median age of 33 years, with 70% female and 38% at WHO stage 4 disease.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 0.582–0.781
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website